Title
Category
Credits
Event date
Cost
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Updates to Management of Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Best Practices for Oncology Urgent Care
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Oncology urgent care is an emerging area of interest requiring many clinical and practical considerations for implementation. Education is needed on the value of offering oncology urgent care and the factors that lead to successful programs.
Expansion of Recommendations for Hereditary Cancers
  • Genetic/Familial High-Risk Assessment
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for gastroesophageal tumors is expanding, including the role of systemic therapy plus surgery. It is essential for healthcare professionals (HCPs) in community and academic settings to be aware of and understand current and emerging treatment options and associated evidence, even that which is limited and may be controversial.
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors
  • Neuroendocrine Tumors
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As there are no data to support a specific sequence of regional versus systemic therapy or to guide sequencing of systemic therapy options, it is important for physicians to be aware of the available treatment options and emerging data on novel therapies so they can provide individualized care for their patients.
Team-Based Case Review: Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.
Updates to the Management of Cervical Cancer
  • Cervical Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The systemic therapy section of the NCCN Guidelines for Cervical Cancer has continuously added new IO therapy options over the past few years to reflect the new approvals. Knowledge in this topic will guide the practitioners in appropriately prioritizing these new treatment options to further improve patient outcomes. 
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Additionally, clinical approach for all uncommon histologies of ovarian cancer including rare malignant germ cell tumors can be variable.
Advances in Head and Neck Cancers: Nasopharyngeal and Oral Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing and preventing sequelae following surgery, radiation therapy (RT), and systemic therapy (e.g., trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, renal failure) requires professionals familiar with head and neck cancers. Limited data are available comparing the efficacy of different chemoradiotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN). Immunotherapy options for recurrent/metastatic nasopharyngeal cancer is a rapidly evolving area of research.

Pages